Moclobemide in the treatment of social phobia.
Social phobia is a common disorder which is associated with considerable suffering and impairment. Effective treatments have now been developed and they represent an important advance in the management of the disorder. Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression. The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebo-controlled studies. It has also proved to be effective in long-term treatment in a placebo-controlled study and in open treatment studies. This paper reviews the efficacy of moclobemide in social phobia.
Nutt
D
D
School of Medical Sciences, University of Bristol, UK.
Montgomery
S A
SA
D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy*
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide